Sangamo Biosciences Inc (SGMO)

[surf1944]

7:07AM Sangamo BioSci announces nature biotechnology study demonstrating the use of Zinc finger nucleases to generate HIV resistant human stem cells (SGMO) 3.64 : Co announces the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus based on its proprietary zinc finger DNA-binding protein nuclease technology. The ZFN approach enables the permanent disruption of the CCR5 gene, which encodes an important receptor for HIV infection, in all the cell types comprising the immune system that develop from hematopoietic stem cells (HSCs), and is the basis for a promising therapeutic strategy for the treatment of HIV/AIDS. Sangamo has two ongoing Phase 1 clinical trials to evaluate the safety and clinical efficacy of this approach in CD4+ T-cells.